

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Bio-heart Biological Technology Co., Ltd.** **上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

### **INSIDE INFORMATION PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the requirements of the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Company hereby announces that, on September 5, 2022 (after trading hours), the board of directors (the “**Board**”) of the Company has resolved and approved to commence the relevant preparation related to the proposed initial public offering of ordinary shares of the Company traded in Renminbi and listing on the Sci-Tech Board of the Shanghai Stock Exchange (the “**Proposed A Share Offering**”).

Under the existing requirements of the China Securities Regulatory Commission (中國證券監督管理委員會) (the “**CSRC**”), the Company is required to engage a pre-listing tutoring institution to provide tutoring services to the Company before the making of the listing application for the purpose of the Proposed A Share Offering, and such services are monitored by the CSRC in the place of establishment of the Company. The acceptance of the registration application for pre-listing tutoring does not represent that the Company has (i) fulfilled the criteria for the making an application for the Proposed A Share Offering; nor (ii) applied for the Proposed A Share Offering with the CSRC or the relevant stock exchange. The Board is pleased to announce that in connection with the Proposed A Share Offering, the Company has engaged Huatai United Securities Co., Ltd (華泰聯合證券有限責任公司) as the pre-listing tutoring institution and will submit the registration application for pre-listing tutoring with CSRC. Huatai United Securities Co., Ltd has also been appointed as an underwriter of the Proposed A Share Offering.

As at the date of this announcement, the Company has not formulated the offering plan and structure of the Proposed A Share Offering, and has not applied to any of the relevant regulatory authorities in the People's Republic of China for approval of the Proposed A Share Offering. The Board will consider and, if thought fit, approve the definitive offering plan, and convene a general meeting and/or class meetings for shareholders' approval in respect of the Proposed A Share Offering pursuant to requirements under the articles of association of the Company.

**Shareholders and potential investors of the Company should note that the Proposed A Share Offering is subject to the approval of, among others, the Board and the general meeting of the Company, the CSRC, and other competent regulatory authorities. As such, the Proposed A Share Offering may or may not proceed, and there is no assurance that the Proposed A Share Offering will materialize or as to when it may materialize. Shareholders and potential investors of the Company should therefore exercise caution, and only place reliance on the information published by the Company, when they deal or contemplate dealing in any securities of the Company. If in doubt as to their positions or the actions to be taken, Shareholders and potential investors of the Company are strongly recommended to consult their professional advisers.**

**This announcement is for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe for the share(s) of the Company. Further announcement(s) will be made by the Company in accordance with the Listing Rules and other applicable laws and regulations of any material updates and progress in connection with the Proposed A Share Offering as and when appropriate.**

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People's Republic of China, September 5, 2022

*As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU and Mr. Ji CHEN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.*